TECH OFFER

Bladder Cancer Diagnostic

KEY INFORMATION

TECHNOLOGY CATEGORY:
Healthcare - Diagnostics
TECHNOLOGY READINESS LEVEL (TRL):
LOCATION:
Australia
ID NUMBER:
TO126838

TECHNOLOGY OVERVIEW

An immunocapture device that specifically captures bladder cancer cells from urine for analysis.

Bladder cancer is on average the 9th most common (the chance of developing bladder cancer is 1 in 27 for men and 1 in 89 for women), and of all cancers, the most expensive to treat from diagnosis to death because of its particularly high recurrence rate (<70%) and the associated patient life-long surveillance required. The current gold standard for initial diagnostic and monitoring is cystoscopy. This procedure is costly and invasive, and therefore no preventive screening is offered to the general population. Early diagnosis is important as patient outcomes are much better for bladder cancer diagnosed locally in the bladder and having not penetrated the surrounding muscle (Muscle Invasive Bladder Cancer) or to other parts of the body.

The current clinical and technical challenge is to develop a noninvasive, easy to implement, costeffective and accurate technique capable of detecting early stages of bladder cancer and its recurrence.

TECHNOLOGY FEATURES & SPECIFICATIONS

Urine is a promising vector for noninvasive diagnostic as it contains both molecular and cellular cancer biomarkers. To date, tests developed to detect molecular biomarkers in urine haven’t had sufficient specificity to progress as a clinical diagnostic.

We have developed a test that uses a novel device to capture whole cancer cells from urine. Our device processes a urine sample from POC to cell analysis with minimal manual handling. The device incorporates a custom-designed microfluidic channel that has been coated with a novel plasma polymer coating which uniquely facilitates the covalent binding of bioactive capture antibodies. The cell capture device is designed to be used in conjunction with current microscopes for cell analysis.

POTENTIAL APPLICATIONS

This technology is relevant for the biomedical point of care diagnostic market.

Benefits

  • Non-invasive 
  • No pre-processing of urine sample required 
  • Significant improvement over current cytology approaches
RELATED TECH OFFERS
Therapeutic Inhibitor for Epstein-Barr Virus (EBV)-associated Cancers
Cancer Catcher - Early Detection of Circulating Tumour Cells
Non-invasive Alzheimer’s Disease Diagnostic Kit
Sleep Apnea Detection Using Smart Hearables
Robotic Capsule Endoscope for GI Tract Inspection
Non-invasive First-void Urine Device for Rapid Detection of Infectious Diseases and Cancer
“Ex-vivo Navigation Drug” – Active Visualization for Extracorporeal Surgical Operation
Novel Marker for High Sensitivity Detection of Human DNA
Novel Drug for Cancer Diagnostics and Photodynamic Treatment
An In-Vitro Digestion Model Mimicking The Stomach Conditions